Teva Pharmaceutical Industries Limited (TEVA) Valuation
Historical valuation analysis based on 500 data points (2024-09-27 to 2026-09-25)
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total nu...
Teva Pharmaceutical Industries Limited (TEVA) currently trades at a P/E ratio of 29.52 (historical range: 22.10–59.13, median: 30.83), placing it at the 47th percentile — near its historical average, P/S ratio of 2.66 (range: 0.89–2.73, 99th percentile — expensive relative to its history), EV/EBITDA of 19.68 (range: 10.83–55.78, 48th percentile).
Teva Pharmaceutical Industries Limited trades above its historical valuation range, with most metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 29.52 | 22.10 | 30.83 | 59.13 | 47th | near its historical average |
| P/S Ratio | 2.66 | 0.89 | 1.41 | 2.73 | 99th | expensive relative to its history |
| EV/EBITDA | 19.68 | 10.83 | 19.91 | 55.78 | 48th | near its historical average |
| FCF Yield | 2.54% | 1.37% | 3.64% | 8.25% | 24th | above its historical average |
Teva Pharmaceutical Industries Limited (TEVA) Valuation & P/E History
Teva Pharmaceutical Industries Limited (TEVA) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry currently trading at $39.19 with a market capitalization of $45.7 billion. This page provides historical valuation analysis for TEVA based on 500 data points covering 2024-09-27 to 2026-09-25. The P/E ratio of 29.52 is below the historical median of 30.83, placing TEVA at the 47th percentile of its valuation range. The P/S ratio of 2.66 compares to a median of 1.41.
TEVA Valuation Metrics & Historical Range
The valuation table above shows Teva Pharmaceutical Industries Limited's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether TEVA is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests TEVA is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Teva Pharmaceutical Industries Limited.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is TEVA Overvalued or Undervalued?
Teva Pharmaceutical Industries Limited trades above its historical valuation range, with most metrics above their median levels. The overall valuation percentile of 65 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive TEVA is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full TEVA analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.TEVA trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.